WO1994028129A2 - Tumour metastasis gene - Google Patents
Tumour metastasis gene Download PDFInfo
- Publication number
- WO1994028129A2 WO1994028129A2 PCT/GB1994/001160 GB9401160W WO9428129A2 WO 1994028129 A2 WO1994028129 A2 WO 1994028129A2 GB 9401160 W GB9401160 W GB 9401160W WO 9428129 A2 WO9428129 A2 WO 9428129A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dna
- seq
- nucleic acid
- sequence
- sample
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Abstract
A 2858bp DNA fragment (SEQ ID NO:1) is provided which codes for a protein which is expressed in malignant human tumours and their metastases. The DNA fragment is useful in diagnosing or assessing the prognosis of metastasis of a patient.
Description
TUMOUR METASTASIS GENE
Background
Metastatic spread of tumours from the site of primary growth to distant organs, where seedling tumours are formed by disseminated cells, is the most clinically important property of malignant tumours. It endows the community of tumour cells with the ability to survive surgical excision of the primary growth. Also, because metastases can themselves act as foci for further shedding and dissemination of tumour cells, this process forms the basis for a geometric increase in the impact of the tumour on the host and increasing difficulty in clinical management, because of the wide dispersal of the tumour burden. The magnitude of the effect of this phenomenon on human health can be appreciated by reference to the mortality statistics published by the Registrar General of the United Kingdom. Approximately one in three of the population die of the consequences of metastatic cancer, or are found to harbour asymptomatic metastatic tumour deposits at autopsy. Research to obtain data which could be helpful in early assessment of tumour prognosis or in preventing the growth of already established metastases is therefore directed at controlling a major and clinically significant problem. The following work was undertaken as a contribution to such an endeavour.
Current Work
In work recently conducted in the inventors laboratory it has been found that, if one is sufficiently persistent, it is feasible to transfer metastatic capability from human metastatic tumour
cells to non-metastatic mouse tumour cells, by transfection with genomic DNA from the metastatic population (Tarin 1988). On inoculation into nude mice the transfected cells make many metastatic deposits in various organs. The new phenotype is stable through many cell generations and can be transferred again in a second round of transfection, using DNA from metastases formed by the primary transfectants which we have introduced into fresh cells of the non-metastatic mouse cell-line. Subsequently it has been demonstrated in this programme of work that concomitant transfer of the donor DNA (of human origin) through both rounds of transfection, can be detected by several convergent lines of evidence, including Southern blotting, Alu-PCR and in situ hybridisation (Hayle, Darling, Taylor and Tarin, 1993) using human Alu-specific probes with appropriate controls. Still more recently this work has led to the isolation of clones containing human DNA, from the transfected metastatic cells by making a genomic library of their DNA, in cosmids and screening it with human Alu specific probes. From one of the bacterial clones so identified it was possible to subclone a 2.9 Kb DNA Fragment that hybridises specifically to Southern blots of human DNA to identify 5 a sharp homologous band suggestive of a sequence present in single or low copy number. This indicates that the homology is not to multiple iterative sequences, present in the human genome, which would have been expected to produce a smear. (It should be Q mentioned that, to visualise the band, non-specific cross hybridisation of Alu repeats in the probe to counterparts in the target human DNA, was blocked with excess unlabelled Alu DNA prepared by PCR) .
The fragment has been sequenced and c comparison of this information with entries in the
GenBank/EMBL DataBank, indicates that it contains human
DNA which has not been previously recorded. Further analysis of the sequence by computer programmes to detect coding regions as well as by Northern blotting and by reverse transcription-poly erase chain reaction (RT-PCR) techniques, has provided converging lines of evidence that parts of it are vigorously transcribed (expressed) in malignant human tumours and their metastases, but not comparably so in non-neoplastic tissue. The significance of this finding is that the sequence has the potential to be a valuable probe for the accurate assessment of the prognosis of patients with malignant tumours, by examination of a tiny biopsy sample or even a few cells obtained by fine needle aspiration, and thus to influence therapy. 5
The Invention
The invention provides the 2858bp DNA whose sequence (SEQ ID NO: 1) is shown in the Figure.
The invention also provides a nucleic acid o which codes for a protein which is expressed in malignant human tumours and their metastases, which nucleic acid is selected from: the 2858bp DNA whose sequence (SEQ ID NO: 1) is shown in the figure, degenerated and allele variations thereof, fragments 5 thereof, longer DNA chains comprising any of these, and DNA which hybridises to any of these.
The nucleic acid can be incorporated into an expression vector, and the vector into a microorganism. The expression vector and the transformed microorganism Q constitute further aspects of the invention.
In another aspect, the invention provides use of the defined nucleic acids or derivatives or fragments thereof for the identification, preparation or isolation of the nucleotide sequence or portions thereof coding for a protein which is expressed in malignant human tumours and their metastasis. Thus the
inventor intends to proceed with blotting, PCR and library screening techniques, to search for related flanking sequences and cDNA clones. In this way, it is hoped to recover stretches of human DNA which are worth testing in functional assays to evaluate their metastatic inductive capability. These experiments may include reintroduction of the defined expression vectors into non-metastatic tumour cell lines.
The invention also provides a method of investigating metastasis which method comprises obtaining a sample of cells, and analysing the sample for the nucleic acid of the 2858bp nucleic acid fragment or for a complementary RNA sequence. This analysis may preferably involve the use of reverse transcriptase to form cDNA corresponding to RNA of the sample; amplifying the cDNA, e.g. by the polymerase chain reaction; and performing a hybridisation assay of the amplified DNA using as a hybridisation probe a fragment or the whole of the defined DNA. Tne sample of cells may be a clinical sample of body fluid (e.g. blood, urine, sputum or stool) or body tissue (e.g. tumour tissue) of a patient. The sample may be a histological section which is probed using a fluorescent or other labelled probe for mRNA corresponding to the 2858bp nucleic acid fragment.
E perimental
Computer analysis has indicated that the sequence contains sections with characteristics signifying high probability that they are coding regions. Several studies were performed on this 2.9 Kb fragment to examine its informational content using various suites of programmes available via the Oxford University VAX cluster. These included looking for coding sequences by locating the positions of potential
start codons and by seeking stretches which have no stop codons. Further methods used included codon preference analysis (i.e. examination of whether the order of arrangement of purine and pyrimidine bases is characteristic of coding sequences), as well as searches for probable splice junction sites and other more specialised techniques, to confirm that some of the open reading frames so detected are coding regions. This information was used to design PCR primers to the boundaries of one of the coding regions which particularly attracted interest and with the RT-PCR technique showed that one could specifically amplify homologous mRNA sequences from RNA extracted from metastatic human tumour cell lines. The exact sequences of the primers used was as follows: P1 5 'AATGACCCAGGAATGTCCAGGCCC (SEQ ID NO: 2) P2 5 'GAGGAGCACCTCACAGGCATCAAA (SEQ ID NO: 3) P3 5 'ACGTGTCGCAGAGCAGTGTGCTGT (SEQ ID NO: 4) P4 5 'TCTCACACCCATCTGGCTCCCACA (SEQ ID NO: 5) and the positions of these are marked on the sequence above.
Computer analysis of the sequence of the new DNA fragm nt The sequence was analysed using the Genetics
Computer Group (GCG) package on the Oxford University molecular biology VAX cluster, the BLAST network service at NCBI and the mail servers Grail, Netgene and GenelD. The Grail mail server is trained to recognised Q potential coding regions in human DNA; NetGene also uses a neural network to approach to predict splice sites in vertebrate genes; and the GenelD mail server uses a hierarchical rule based system to recognise potential vertebrate coding genes. c Database searches were made at Oxford against
EMBL release 34.0 and SwissProt release 25 and at NCBI
against the non redundant DNA database (containing EMBL release 34.0 and GenBank release 76.0) and the non redundant protein database (containing SwissProt release 25, PIR release 36 and GenPept release 76). The DNA sequence was searched against the
EMBL and Genbank databases using the GCG implementation of the FASTA program and the NCBI BLAST service to look for homologies to any known sequences. No homology to any known coding regions were found. At the 3' end a strong homology to a rodent Alu-like repetitive sequence was found, suggesting that the 3 ' end contains a rodent sequence. The remainder of the DNA fragment contained scattered sequences with similarity to higher primate Alu repeats and several short segments with familial resemblances to sections of a variety of human genes, but no significant resemblances to rodent genes. This supports the Southern blotting data that the cloned sequence is mainly a portion of human genomic DNA retrieved from the mouse genome of the cells into which it was transfected. The sequence, translated in all six frames, was searched against the protein databases. No homologies to any known protein sequences were seen.
The GCG program CodonPreference was used to display potential open reading frames (i.e. stretches of sequence without a frame stop codon) ; and to predict the likely coding regions, based on the degree of codon bias shown towards a reference codon usage set of highly expressed human genes. The level of GC bias and codon usage bias were seen that corresponded to possible open reading frames (ORFs). Among the most notable is the region from approximately bases 1650 to 1800 in the 2nd reading frame of the reverse strand.
The entire sequence was submitted to the NetGene, GenelD and Grail mail servers to detect potential splice sites, genes and exons. Grail
predicted three possible exons, one in the forward strand in frame 2 (between bases 536 and 942) and two in the reverse strand, in frames 1 (between bases 2143 and 2398) and 2 (between bases 1625 and 1907). These three regions all corresponded to exons predicted by GenelD and also to donor and acceptor sites found by NetGene (see Table 2) . All three exons fell within regions of higher than expected codon preference and GC bias as predicted by CodonPreference analysis. The region around the possible exon in the second frame of the reverse strand was therefore the first one chosen for further study, being the one with the highest probability of being a coding region.
The whole DNA sequence was also examined for potential transcription factor coding domains and binding sites by searching against the release 6.3 of the Ghosh database using GCG FindPatterns. Although some tentative matches were found a detailed study of the compositions of these and their locations in the three reading frames indicated that these were all very unlikely to be true transcription factor coding regions. The translated sequence was also searched against release 10.1 of the Prosite database to search for potential DNA binding regions using the GCG program Motifs, but no homology to previously recorded regions could be identified.
Investigation of expression
Evidence that one of the putative coding regions identified by computer analysis in this fragment is expressed in neoplastic or metastatic tumour tissue, was provided by experiments using the techniques of Northern blotting and RT-PCR. Northern blots of mRNA from metastatic cell lines A375M (the donor of the DNA used for the original transfection of metastatic behaviour) and 4A4 (a clonal line derived
(Bao et al. 1992) from the human breast carcinoma cell line MDA-MB-435) probed with a 32P labelled sample of the full 2858 base pair sequence showed specific hybridisation to two small transcripts of approximately 300bp size, but no comparable homology to mRNA from a virtually non-metastatic cell line 2C5 cloned from MDA-MB-435.
Reverse Transcription - Polymerase Chain Reaction (RT-PCRϊ Messenger RNA extracted from cell lines and solid tissue samples was reverse transcribed with viral reverse transcriptase and the cDNA so obtained specifically amplified with primers P1 and P4 designed to anneal to the outer ends of the putative coding region identified by computer analysis between base 951 and 1233 on the reverse strand of the 2858 base pair complete sequence. Samples were also amplified using primers P2 and P4. The PCR products were separated by gel electrophoresis in 1.6% agarose and stained with ethidium bromide for viewing in a U-V transilluminator. After photography the gels were blotted on to Hybond N+ (Amersham International pic) nylon membranes and probed with 32P gammaATP end-labelled oligonucleotide P3. After hybridisation the filters were washed and exposed to Kodak x-ray film for 2-10 hours, after which the film was developed.
The PCR cycle parameters were as follows: 1 period at 94'C for 4 minutes, followed by 1 period at 82'C for 2 minutes, during which time the Taq enzyme was added, followed by 30 cycles of 92'C for 30 seconds, 60°C for 30 seconds and 70°C for 2 minutes. Control studies to monitor the quality of mRNA and the success of cDNA synthesis in the RT-PCR techniques were conducted using 2 μl aliquots from the same samples amplified with primers to the human β- actin gene (Clontech Laboratorie Inc., Palo Alto, CA) .
When blots of PCR products of cDNA obtained by reverse transcription of mRNA from these cell lines and amplified by primer pairs P1 and P4 and P2 and P4 were probed with oligonucleotide P3 strong hybridisation was seen to bands of the predicted sizes in the tracks containing samples from the metastatic cells (A375M and 4A4) and weak hybridisation to similar sized bands in the track containing sample from the virtually non-metastatic cell line [2C5].
10 Evidence of expression of the coding region in tissues from human primary tumours and their metastases has also been obtained using RT-PCR with the primers chosen. In a preliminary survey of fresh samples from such lesions and from normal tissue
-|c counterparts (Table 1) disproportionately large quantity of specific PCR product corresponding to the amplified segment was observed in samples from metastases and matched primary tumours from all 4 malignant cases studied. In 9 samples from
2o corresponding normal tissues only trace expression was detectable. This trace was not visible on ethidium bromide stained gels and required blotting and probing with 32P labelled oligonucleotide P3 to be detected (Table 1) .
2 Samples from 2 benign tumours showed very low expression (Table 1). Collectively these results confirm that the coding region identified in the 2858 bp cloned DNA fragment is expressed in the malignant tumours examined and indicate that homologous
30 transcripts are present only in trace amounts in the non-neoplastic tissue samples. Expression was also low in the benign (i.e. non-invasive non-metastatic) tumours studied.
35
TABLE 1
RESULTS OF CLINICAL SAMPLES EXAMINED FOR MAGNA GENE
EXPRESSION
Patient Sample MAGNA gene β-actin number expression result expression
Lymph node metastases Breast carcinoma +++ Primary Breast carcinoma ++
Lymph node metastases Breast carcinoma ++ Primary Breast carcinoma +++
Lymph node metastases Breast carcinoma Primary Breast carcinoma
Lymph node metastases Colon carcinoma
Primary Colon carcinoma +++
Adenoma Colon ++
5 Primary Colon carcinoma
6 Fibroadenoma Breast +
7 Fibroadenoma Breast +
8 Normal Breast ±
9 Normal Breast -
10 Normal Breast ± a Normal Breast ±
12 Normal Breast ±
13 Normal Colon
14 Normal Colon
15 Normal Colon
16 Oi erticul ltis Colon
4.J.+ Verv Strong + Weak ++ Strong ± Trace - Nothing
Useful cases
I) 9 non-neoplastic n) 2 fibroadenoma in) 4 metastatic cancer iv) 1 non-metastatic cancer v) 1 colonic adenoma (from patient 4 who is also in
Category in above)
Footnote β-actin expression was determined in an aliquot from each sample as a control to evaluate quality of mRNA obtained from the sample
TABLE 2
SUMMARY OF COMPUTER ANALYSIS OF MAGNA SEQUENCE FOR
CODING REGIONS
BASE PROGRAM FEATURE
Forward Strand Frame 2
539 Grail Extent of ORF
559 NetGene Acceptor Site
560 GenelD Exon Start
869 GenelD Exon End
870 NetGene Donor Site
901 Grail Extent of ORF
Reverse Strand Frame 2
1628 Grail Extent of ORF
1655 GenelD Exon Start
1792 GenelD Exon End
1793 NetGene Donor Site
1906 Grail Extent of ORF
Reverse Strand Frame 1
2146 Grail Extent of ORF
2149 GenelD Exon Start
2389 GenelD Exon End
2390 NetGene Donor Site
2397 Grail Extent of ORF
REFERENCES
1. Tarin, D., Molecular Genetics of Metastasis In: Ciba Foundation Symposium on Metastasis, eds: Whelan J, Bock G R: John Wiley & Sons Ltd, London, 1988, pp 149-169.
2. Hayle, A. J., Darling, D. L., Taylor, A. R., Tarin, D. Transfection of metastatic capability with total genomic DNA from metastatic tumour cell lines Differentiation, 54: 177-189, 1993.
SEQUENCE LISTING
(1) GENERAL INFORMATION: (i) APPLICANT:
(A NAME: ISIS INNOVATION LIMITED (B STREET: 2 South Parks Road (C CITY: Oxford (E COUNTRY: United Kingdom (F POSTAL CODE (ZIP) : 0X1 3UB
(A NAME: TARIN, DAVID (B STREET: Honey Cottage, 58 Tree Lane, Iffley, (C CITY: Oxford (E COUNTRY: United Kingdom (F POSTAL CODE (ZIP) : 0X4 4EY
(ii) TITLE OF INVENTION: TUMOUR METASTASIS GENE (iii) NUMBER OF SEQUENCES: 5
(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25 (EPO)
(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: GB 9311130.0
(B) FILING DATE: 28-MAY-1993
(2) INFORMATION FOR SEQ ID NO: 1:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2858 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(ix) FEATURE:
(A) NAME/KEY: primer_bind
(B) LOCATION: complement (964..987)
(ix) FEATURE:
(A) NAME/KEY: primer_bind
(B) LOCATION: complement (1091..1114)
(ix) FEATURE:
(A) NAME/KEY: primer_bind
(B) LOCATION: 1141..1164
(ix) FEATURE:
(A) NAME/KEY: primer_bind
(B) LOCATION: 1206..1229
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
TTCCAGCTCC ACCTCCCGAG TTGCTGGAAT TATAGGTGTC TGTCTGCCGC CACTCTCAGT
TTATGCAGGG CTGGGGTCTG AACCCAGGGC TTTGTGCAAA GGAGGCAATG CCCAAAACCA 1
CACTACACTC CCTACGTCCT CCACCATTTT TAGTAAAATG TCAAGCCCAA AACTACTCTG 1
CCAATTCGCT CAAGTGGAAC CACCTGTCTC CCTGCCACAC CCTATTAAGC CTATAGGTGG
AGGCCAGCGC CACTCTCAAG CCTGGCCCAC CCCACCCCAG AAGTGCCTCC CCCCCACCAG 3
ATCCAGGTCC TCCACCGTAT TCCCCAACTC ATGGTTCCAA GGTTAATTCT AGAATGCGTA 3
CCCAAAGCCA ATAGCCCACC AGACACAACA GACTGCCTTC TCATGAACTA GGCCATGATC 4
AAACAGCTGC CCCCCACACA CACACACAGG TCCCCCATTC AGTTGGTACC TTTTTGATAG 4
CGGTCAGCTC CCCTGATATC CAGCACCTCC TCAGACAGGC TGGTGGTGAT CTCGCTAGCA
CAAGACTCTT CCTCCTCAGA ACCTGGGCGG GAAGAATTGC AAGGTAGGGG TAGACAGACT
GCAATGCCCA GGACCTGGTA AGAATGTGCA TAAAACCCTA GCCCTTTGGT GGCTAAAGAA
GGATGAGCAG GGAGGGGAGG AGCTTTTAGC CCTAAGACAA CAACAACATC CTGTCACGAC
GGGTACCGGA CTTATAGCAA AGAGCCTGGG AAATTGGCGA GACTATGTGG AAGAGAAGTT
GATGGTGGCG GCGGAGATCC AGAGTCTGGG TCAAAGAAGC ATGAACATGG AAAGGGGGTC
CAGGAAGGAT AACTTCAGAG AGCAGACAGG TAAGGCATGT CCAACAAGGA GAAGAGGTTT
CTAGAGTCAC ACAAATCTAA CAGAGCTGGG TACCTCTCAG AGATGGCTGC TAAGGTGGTG
AGAAATGACC CAGGAATGTC CAGGCCCCAC CCCCATCCTG CAGGAGAGAA GTCCCTCCTC 1
TCCTGATGCT CCCTCCTCCC TCTCCTGATG CTCCCTCCTC CCTCACCTCA TTCTCGGAAG 1
AACTGGCAGA GAGGAGCACC TCACAGGCAT CAAAGAACTC GGTGTGGGAG TCGGCGAGGG 11
ACAGCACACT GCTCTGCGAC ACGTGGGGGG TCAGCTCTCG GCCTTTCATG TACAGAGCTT 1
CTTGCTGTGG GAGCCAGATG GGTGTGAGAC CTCAGAGGCC ACTGGAGTGA CAGACTTCCT 1
GGAGTGGGAA CTATCACCCC CCACCCTCCT GCCAAGCAGA AGTAGCAAAA GAGAGGAAGA 1
GCTTAAGGGA GAGGGAAAAT CTTGGACTTA GAAGAGAGGC TGGGCACCAA TAGAGCCTAG 1
CTCCACCCTT CTCCTTGTTT GTTTTGTTTT GTTTTTTCTC TGTGTAGCTC TGGCTGTCCT 1
CGGAACTCAC TTTGTAGACC AGGCAGGCCT AAAACTCAGA AATACCCTGC CTCTCCTCCT 1
CTCAAGTTCT GGGATTAAAG GCGTGTGCAC CACCGCGGCC ACTCTTCTCC TTCCTGACCC 1
ACTCAGCTCG GAACCACACC CCATGGACAG GTGCAGTTAT GTCTCCACTT TGCAGATTAG 1
AAGACTGAGG CTCAGAATAC AAGCTGGCAT GCACACCACC CTCAGACTCT AATTCAGCCT 1
GGCTACTACT GAGGGTCCAT GAACCGGTCG ACTTAGTTAT TCTTTGGGTT TTACGTTTTG 1
TGATGCAGAT ATGTCTGACC TGTGGCCCAT GAGCTGTACA CAAATGAATG CAGACTAATG 1
CAAAATCATA AACTTACTCA AAACATTATG AAAATAGTTT GCACGAACTT TCTTTGTTGT 1
TATTAAGTTG TTATACATTT TTGTTGGCTT GTTTTTTTGT TTTTTGGGAT TTTTTGTTTT "1
TTTTTTTTTT TTGGTTTTTT TGAGACAGGG TTTCTCTGTG TAGCCCTGGC TGTTCTGGAA 1
CTCAACTTTG TAGACCAGGC TGGCCTAAAG TCAGAAATCT GCCTGCCTCT GCCTTCCGAG 2
TGCTGGGATT AACAGTAGGG CCACCACGCC CGGCTCCTTC TTTCTTTCTT TCTTTCTTCC 2
TTTCTTTTTC GGTTTTTCAA GACAGGGTTC TGCTGTGTAG CCCTGGCTTT CCTGAACTCA 2
GAAATCTGCC TGCCTCTGCC TCCCAAGTGC TGGGATTAAA GGCATGTGCA ACTGCCTGGC 2
TTTTCTTTAT TTTGTGTTTT TTTTTAAATT TAATATTTAT TGTATGTGAG TACACTGTCA 2
CTGCTTCAGA CACACCAAAA GAGGGCGATC AGATCACATT ATAGATGGTT GTGAGCACCG 2
ATGTGGTTGG TACTGAGAAT TAAACTCAGG ACCTCTGGAA GAGCAGTCAG TGCTCTTAAC 2
CACTTAGCCA TCTCTCCAGC CCTGTTTGTT TTTTCAAGAC AGAGTTTCTC TGTGTAGCCC 2
TGGCTGTCCT AGAACCCACT CTGTAGACCA GGCTGGCCTC AAATTCAGAG ATCCACCTGC 2
CTCTGCCTCC CAGGTGCTGG TCTACAGGGG AAGATTATGT TGTCCTTGGG TATGTCCTTA 2
GGTAATGTCA AAGGCTGGAC AGGCCTGCTA AAGGGTAAGA ACCAACGCCT CACGGGCTCT 2
GAAGTAAAAG GTAAAAATGT CCTCAGAAGC CAGAATATGG CTCAGATGCA GACTTCTGGC 2
CTAGCATGCA AGGCCCTGTG TTCACGCCTC AGTACTACAA CCAACCCAAC CCAACCCAAC 2
CCAACCCAAC CCAACCAACC CAACCCAAAA TATGATGCAC AAGCCATCTA CAGGAGCAGT 2
CAAGAGAACT GTAGTGTTAT GTGAGAGAAA GGGAAGCT 2
(2) INFORMATION FOR SEQ ID NO: 2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2
AATGACCCAG GAATGTCCAG GCCC
(2) INFORMATION FOR SEQ ID NO: 3:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3 GAGGAGCACC TCACAGGCAT CAAA
(2) INFORMATION FOR SEQ ID NO: 4:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4 ACGTGTCGCA GAGCAGTGTG CTGT
(2) INFORMATION FOR SEQ ID NO: 5:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5 TCTCACACCC ATCTGGCTCC CACA
Claims
1. The 2858bp DNA whose sequence is shown in the figure (SEQ ID NO: 1).
2. A nucleic acid which codes for a protein which is expressed in malignant human tumours and their metastases, which nucleic acid is selected from: the 2858bp DNA whose sequence is shown in the figure, degenerated and allele variations thereof, fragments thereof, longer DNA chains comprising any of these, and DNA which hybridises to any of these.
3. An expression vector comprising the nucleic acid of claim 1 or claim 2.
4. A transformed microorganism comprising the expression vector of claim 3.
5. Use of the nucleic acid of claim 1 or claim 2 or derivatives or fragments thereof for the identification, preparation or isolation of a nucleotide sequence or portion thereof coding for a protein which is expressed in malignant human tumours and their metastases.
6. A method of investigating metastasis which method comprises obtaining a sample of cells, and analysing the sample for the nucleic acid of claim 1 or claim 2 or for a complementary RNA sequence.
7. A method as claimed in claim 6, wherein the sample of cells is a clinical sample obtained from body fluid or body tissue of a patient.
8. A method as claimed in claim 6 or claim 1 , which method comprises making cDNA from mRNA in the sample, amplifying a portion of the cDNA comprising at least part of the DNA of claim 1 , and detecting the amplified DNA.
9. A method as claimed in claim 8, wherein the cDNA is amplified by means of the polymerase chain reaction using as primers
P1 5 'AATGACCCAGGAATGTCCAGGCCC (SEQ ID NO: 2) or
P2 5 'GAGGAGCACCTCACAGGCATCAAA (SEQ ID NO: 3) and
P4 5 'TCTCACACCCATCTGGCTCCCACA (SEQ ID NO; 5)
10. A probe which is a labelled oligonucleotide
P3 5 'ACGTGTCGCAGAGCAGTGTGCTGT (SEQ ID NO: 4) .
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002149633A CA2149633A1 (en) | 1993-05-28 | 1994-05-27 | Tumour metastasis gene |
| EP94916320A EP0700436A1 (en) | 1993-05-28 | 1994-05-27 | Tumour metastasis gene |
| JP7500405A JPH09504682A (en) | 1993-05-28 | 1994-05-27 | Tumor metastasis gene |
| AU68022/94A AU6802294A (en) | 1993-05-28 | 1994-05-27 | Tumour metastasis gene |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9311130.0 | 1993-05-28 | ||
| GB939311130A GB9311130D0 (en) | 1993-05-28 | 1993-05-28 | Tumor metastasis gene |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1994028129A2 true WO1994028129A2 (en) | 1994-12-08 |
| WO1994028129A3 WO1994028129A3 (en) | 1995-02-02 |
Family
ID=10736338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB1994/001160 WO1994028129A2 (en) | 1993-05-28 | 1994-05-27 | Tumour metastasis gene |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0700436A1 (en) |
| JP (1) | JPH09504682A (en) |
| AU (1) | AU6802294A (en) |
| CA (1) | CA2149633A1 (en) |
| GB (1) | GB9311130D0 (en) |
| WO (1) | WO1994028129A2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997018454A2 (en) * | 1995-11-16 | 1997-05-22 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| WO1997025443A1 (en) * | 1996-01-10 | 1997-07-17 | The University Of Liverpool | Metastasis inducing dna's |
| US5783182A (en) * | 1996-01-30 | 1998-07-21 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| US6252058B1 (en) | 1997-11-05 | 2001-06-26 | Timothy C. Thompson | Sequences for targeting metastatic cells |
| US6545139B1 (en) | 1998-03-13 | 2003-04-08 | Baylor College Of Medicine | DNA sequence encoding the p99 gene and kits for the detection of neoplasia |
| USRE38392E1 (en) | 1996-01-30 | 2004-01-20 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| USRE38490E1 (en) | 1995-11-16 | 2004-04-06 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| US7462491B2 (en) | 2002-01-31 | 2008-12-09 | Baylor College Of Medicine | Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049662A (en) * | 1987-10-13 | 1991-09-17 | The United States Of America As Represented By The Department Of Health And Human Services | Kit for diagnosing cancer metastatic potential |
| WO1992000757A1 (en) * | 1990-07-09 | 1992-01-23 | Research Corporation Technologies, Inc. | Diagnosis of metastatic cancer by the mts-1 gene |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4064113A (en) * | 1973-06-15 | 1977-12-20 | Alelio Gaetano F D | Aminophthalic anhydride copolymers |
| US4131730A (en) * | 1975-05-12 | 1978-12-26 | Alelio Gaetano F D | Modified polyamic acid from aminophthalic acid anhydride and dianhydride |
| JPS61143435A (en) * | 1984-12-15 | 1986-07-01 | Nitto Electric Ind Co Ltd | Moisture-resistant polyimide |
| JPS6213436A (en) * | 1985-07-11 | 1987-01-22 | Nitto Electric Ind Co Ltd | Colorless transparent polyimide molding |
| JPS61226732A (en) * | 1985-03-30 | 1986-10-08 | Nitto Electric Ind Co Ltd | Liquid crystal display element |
| KR930005151B1 (en) * | 1990-05-15 | 1993-06-16 | 재단법인 한국화학연구소 | Process for the preparation of polyesther imide imideresin and thereof |
-
1993
- 1993-05-28 GB GB939311130A patent/GB9311130D0/en active Pending
-
1994
- 1994-05-27 WO PCT/GB1994/001160 patent/WO1994028129A2/en not_active Application Discontinuation
- 1994-05-27 EP EP94916320A patent/EP0700436A1/en not_active Withdrawn
- 1994-05-27 JP JP7500405A patent/JPH09504682A/en active Pending
- 1994-05-27 AU AU68022/94A patent/AU6802294A/en not_active Abandoned
- 1994-05-27 CA CA002149633A patent/CA2149633A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049662A (en) * | 1987-10-13 | 1991-09-17 | The United States Of America As Represented By The Department Of Health And Human Services | Kit for diagnosing cancer metastatic potential |
| WO1992000757A1 (en) * | 1990-07-09 | 1992-01-23 | Research Corporation Technologies, Inc. | Diagnosis of metastatic cancer by the mts-1 gene |
Non-Patent Citations (3)
| Title |
|---|
| BRITISH JOURNAL OF CANCER vol. 62, no. 3 , September 1990 page 544 M. CAIRNEY ET AL. 'Secondary Transfer of metastatic capability and confirmation by PCR of concomitant transfer of donor DNA' * |
| CIBA FOUND. SYMP. ON METASTASIS vol. 141 , 1988 pages 149 - 169 D. TARIN 'Molecular Genetics of Metastasis' cited in the application * |
| DIFFERENTIATION vol. 41, no. 3 , September 1989 , GERMANY pages 208 - 215 J. S. WALLACE ET AL. 'The ras Oncogene and tumor metastasis' * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997018454A2 (en) * | 1995-11-16 | 1997-05-22 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| WO1997018454A3 (en) * | 1995-11-16 | 1997-08-14 | Timothy Thompson | Method for identifying metastatic sequences |
| AU725186B2 (en) * | 1995-11-16 | 2000-10-05 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| USRE38490E1 (en) | 1995-11-16 | 2004-04-06 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| WO1997025443A1 (en) * | 1996-01-10 | 1997-07-17 | The University Of Liverpool | Metastasis inducing dna's |
| US5783182A (en) * | 1996-01-30 | 1998-07-21 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| USRE38392E1 (en) | 1996-01-30 | 2004-01-20 | Baylor College Of Medicine | Method for identifying metastatic sequences |
| US6252058B1 (en) | 1997-11-05 | 2001-06-26 | Timothy C. Thompson | Sequences for targeting metastatic cells |
| US7029859B2 (en) | 1997-11-05 | 2006-04-18 | Baylor College Of Medicine | Sequences for targeting metastatic cells |
| US7666412B2 (en) | 1997-11-05 | 2010-02-23 | Baylor College Of Medicine | Methods for the treatment of neoplastic disorders with anti-caveolin agents |
| US6545139B1 (en) | 1998-03-13 | 2003-04-08 | Baylor College Of Medicine | DNA sequence encoding the p99 gene and kits for the detection of neoplasia |
| US7462491B2 (en) | 2002-01-31 | 2008-12-09 | Baylor College Of Medicine | Methods and compositions for diagnosis and monitoring of prostate cancer progression by detection of serum caveolin |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994028129A3 (en) | 1995-02-02 |
| EP0700436A1 (en) | 1996-03-13 |
| AU6802294A (en) | 1994-12-20 |
| CA2149633A1 (en) | 1994-12-08 |
| GB9311130D0 (en) | 1993-07-14 |
| JPH09504682A (en) | 1997-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Storlazzi et al. | Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma | |
| EP0821733B1 (en) | Genetic markers for breast and ovarian cancer | |
| Shen et al. | Identification of the human prostatic carcinoma oncogene PTI-1 by rapid expression cloning and differential RNA display. | |
| Grønskov et al. | Population-based risk estimates of Wilms tumor in sporadic aniridia: a comprehensive mutation screening procedure of PAX6 identifies 80% of mutations in aniridia | |
| US7807373B2 (en) | Prostate specific gene, PCGEM1, and methods of using PCEGM1 to detect, treat, and prevent prostate cancer | |
| Smith et al. | A transcript map of the chromosome 19q-arm glioma tumor suppressor region | |
| AU735756B2 (en) | Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6 | |
| KR19980702276A (en) | Multi-tumor abnormal growth gene | |
| WO1994028129A2 (en) | Tumour metastasis gene | |
| JP4942248B2 (en) | Prostate specific gene, PCGEM1, and methods of using PCGEM1 for detecting, treating and preventing prostate cancer | |
| US6262247B1 (en) | Polycyclic aromatic hydrocarbon induced molecules | |
| WO1995015334A1 (en) | cDNA PROBE FOR BREAST CANCER DIAGNOSIS AND TREATMENT | |
| CN108315422A (en) | A kind of CLTC-TFEB fusions and its detection primer and application | |
| JP2800850B2 (en) | Methods for detecting neoplasia | |
| US6617104B2 (en) | Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus | |
| Goodison et al. | Rapid analysis of distinctive CD44 RNA splicing preferences that characterize colonic tumors | |
| US20020009720A1 (en) | Plag gene family and tumorigenesis | |
| CN109355388B (en) | Detection kit for identifying cervical cancer genetic susceptibility | |
| EP1179589A1 (en) | MMX-1, a member of the family of human cancer/testis antigens, a protein encoded thereby and a process for determining whether a tumor sample has metastatic potential | |
| Paulsen et al. | Regional localisation of X chromosome short arm probes | |
| US7108977B2 (en) | Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells | |
| JPH05260980A (en) | Human arylamine n-acetyltransferase gene | |
| KR20200001583A (en) | Gender-specific markers for diagnosing prognosis and determining treatment strategies of patient of clear cell renal cell carcinoma | |
| Fukushima et al. | Chromosomal assignments of novel genes expressed in HL60 granulocytes | |
| Liang | United States Patent te |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1994916320 Country of ref document: EP |
|
| ENP | Entry into the national phase in: |
Ref country code: US Ref document number: 1995 428137 Date of ref document: 19950517 Kind code of ref document: A Format of ref document f/p: F Ref country code: CA Ref document number: 2149633 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2149633 Country of ref document: CA |
|
| WWP | Wipo information: published in national office |
Ref document number: 1994916320 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1994916320 Country of ref document: EP |